Certified by Founder Lodge
Frazier Life Sciences
United States - ND
INVESTOR
1 Disclosed Funding Rounds $85,000,000
41 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Frazier Life Sciences invests globally in private and publicly-traded companies that discover, develop, and commercialize innovative biopharmaceuticals. Frazier Life Sciences funds comprise o
| Company | Date | Round | Raised |
|---|---|---|---|
 Attovia Therapeutics |
May, 14 ,2024 | Series B | $105,000,000 |
 Callio Therapeutics |
March, 06 ,2025 | Series A | $187,000,000 |
 Maze Therapeutics |
December, 04 ,2024 | Series D | $115,000,000 |
 Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
 Scorpion Therapeutics |
July, 17 ,2024 | Series C | $150,000,000 |
 Bluejay Therapeutics |
May, 10 ,2024 | Series C | $182,000,000 |
| Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
 Lassen Therapeutics |
December, 21 ,2023 | Series B | $85,000,000 |
 Sudo Biosciences |
December, 21 ,2023 | Series B | $116,000,000 |
| Attovia Therapeutics |
May, 14 ,2024 | Series B | $105,000,000 |
 Radionetics Oncology |
January, 04 ,2024 | Series A | $52,500,000 |
| Maze Therapeutics |
December, 04 ,2024 | Series D | $115,000,000 |
| Maze Therapeutics |
December, 04 ,2024 | Series D | $115,000,000 |
| Scorpion Therapeutics |
July, 17 ,2024 | Series C | $150,000,000 |
| Callio Therapeutics |
March, 06 ,2025 | Series A | $187,000,000 |
| Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
| Callio Therapeutics |
March, 06 ,2025 | Series A | $187,000,000 |
| Sudo Biosciences |
December, 21 ,2023 | Series B | $116,000,000 |
| Bluejay Therapeutics |
May, 10 ,2024 | Series C | $182,000,000 |
| Radionetics Oncology |
January, 04 ,2024 | Series A | $52,500,000 |
 Hillstar Bio |
April, 02 ,2025 | Series A | Undisclosed Amount |
| Maze Therapeutics |
December, 04 ,2024 | Series D | $115,000,000 |
| Attovia Therapeutics |
May, 14 ,2024 | Series B | $105,000,000 |
| Callio Therapeutics |
March, 06 ,2025 | Series A | $187,000,000 |
| Scorpion Therapeutics |
July, 17 ,2024 | Series C | $150,000,000 |
| Callio Therapeutics |
March, 06 ,2025 | Series A | $187,000,000 |
| Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
| Bluejay Therapeutics |
May, 10 ,2024 | Series C | $182,000,000 |
| Maze Therapeutics |
December, 04 ,2024 | Series D | $115,000,000 |
| Hillstar Bio |
April, 02 ,2025 | Series A | Undisclosed Amount |
| Callio Therapeutics |
March, 06 ,2025 | Series A | $187,000,000 |
| Attovia Therapeutics |
May, 14 ,2024 | Series B | $105,000,000 |
| Hillstar Bio |
April, 02 ,2025 | Series A | Undisclosed Amount |
| Scorpion Therapeutics |
July, 17 ,2024 | Series C | $150,000,000 |
 Tubulis GmbH |
October, 16 ,2025 | Series C | $359,197,300 |
| Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
| Maze Therapeutics |
December, 04 ,2024 | Series D | $115,000,000 |
| Callio Therapeutics |
March, 06 ,2025 | Series A | $187,000,000 |
| Hillstar Bio |
April, 02 ,2025 | Series A | Undisclosed Amount |
| Tubulis GmbH |
October, 16 ,2025 | Series C | $359,197,300 |
 Braveheart Bio |
November, 06 ,2025 | Series A | $185,000,000 |
Cherry Ventures
Blue Bear Capital
Slow Ventures
Climate Capital
Eniac Ventures
Tesoro XP, Inc. | $5,400,000 | (Jan 7, 2026)
dazzle ai | $8,000,000 | (Jan 7, 2026)
Truemed | $34,000,000 | (Jan 7, 2026)
Lucidean | $18,000,000 | (Jan 7, 2026)
Lemon Slice | $10,500,000 | (Jan 7, 2026)
